Xu Jianwei, Liu Gang, Wang Xianyao, Hu Ya'nan, Luo Hongyang, Ye Lan, Feng Zhanhui, Li Chen, Kuang Menglan, Zhang Lijuan, Zhou Yixia, Qi Xiaolan
National Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique, Center for Tissue Engineering and Stem Cell Research, Guizhou Province Key Laboratory of Regenerative Medicine, Guizhou Medical University, Guiyang, China.
Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of Medical Sciences, Guiyang, China.
Cytotechnology. 2022 Feb;74(1):17-29. doi: 10.1007/s10616-021-00502-2. Epub 2022 Jan 5.
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are present in human umbilical connective tissue and can differentiate into various cell types. Our previous studies have proved that hUC-MSCs do not lead to allergies and tumorigenesis. In the present study, the acute and long-term toxicity of hUC-MSCs in mice and rats was evaluated. The acute toxicity of hUC-MSCs was assessed in 8-week-old mice receiving two caudal intravenous (i.v.) injections of hUC-MSCs at the maximum tolerated dose of 1.5 × 10 cells/kg with an interval of 8 h and the observation period sustained for 14 days. For the long-term toxicity evaluation, rats were randomly divided into control, low-dose (3.0 × 10 cells/kg), mid-dose (1.5 × 10 cells/kg), and high-dose (7.5 × 10 cells/kg) groups, which were treated with hUC-MSCs via a caudal i.v. injection every 3 days for 90 days. Weight and food intake evaluation was performed for all rats for 2 weeks after the hUC-MSC administration. The animals were then sacrificed for hematological, blood biochemical, and pathological analyses, as well as organ index determination. We observed no obvious acute toxicity of hUC-MSCs in mice at the maximum tolerated dose. Long-term toxicity tests in rats showed no significant differences between HUC-MSC-treated and control groups in the following parameters: body weight, hematological and blood biochemical parameters, and histopathologic changes in the heart, liver, kidneys, and lungs. This study provides evidence of the safety of i.v. hUC-MSCs infusion for future clinical therapies.
人脐带间充质干细胞(hUC-MSCs)存在于人脐带结缔组织中,并且能够分化为多种细胞类型。我们之前的研究已经证明hUC-MSCs不会引发过敏反应和肿瘤形成。在本研究中,评估了hUC-MSCs对小鼠和大鼠的急性和长期毒性。在8周龄小鼠中评估hUC-MSCs的急性毒性,以1.5×10⁶个细胞/kg的最大耐受剂量经尾静脉进行两次注射,间隔8小时,观察期持续14天。对于长期毒性评估,将大鼠随机分为对照组、低剂量组(3.0×10⁶个细胞/kg)、中剂量组(1.5×10⁶个细胞/kg)和高剂量组(7.5×10⁶个细胞/kg),每3天经尾静脉注射hUC-MSCs,共治疗90天。在给予hUC-MSCs后对所有大鼠进行2周的体重和食物摄入量评估。然后处死动物进行血液学、血液生化和病理学分析以及器官指数测定。我们观察到在最大耐受剂量下hUC-MSCs对小鼠无明显急性毒性。大鼠的长期毒性试验表明,hUC-MSCs治疗组和对照组在以下参数方面无显著差异:体重、血液学和血液生化参数以及心脏、肝脏、肾脏和肺的组织病理学变化。本研究为hUC-MSCs静脉输注用于未来临床治疗的安全性提供了证据。